FolateScan in Autoimmune Disease
Study of the Efficacy and Safety of FolateScan (Technetium TC99m EC20) in Patients With Rheumatoid Arthritis and Other Inflammatory Diseases
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Technetium (99mtc) etarfolatide
What it measured
Main measures
detection of joint inflammation due to active rheumatoid arthritis
1 hour post injection of 0.1 mg of EC20
Other measures (1)
detection of systemic organ inflammation due to rheumatoid arthritis
1 hour post injection of 0.1mg of EC20
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Study will include 40 subjects with rheumatoid arthritis (active or inactive disease, defined as no swollen joints) and 5 patients in each of the following diagnosis: osteoarthritis, multiple sclerosis, Crohn's disease, systemic lupus erythematosus, interstitial lung disease and no autoimmune disease (healthy). * Subjects must have disease duration of at least 6 months and creatinine level may not be greater than 1.5 mg/dL.
Exclusion criteria
* Subjects will be excluded if they are pregnant, have an active infection, received an investigational therapy in the past month or previous malignancy within the past 5 years.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study will gather information on the safety of FolateScan and the ability of FolateScan to detect inflammation in the joints and other organs in people with arthritis (rheumatoid arthritis and osteoarthritis), systemic lupus erythematosus, multiple sclerosis, interstitial pneumonitis, Crohn's disease as well as in healthy persons without these conditions.
Papers
Loading reviews and guidelines…
History
Started
Sept 2006
Main results due
Dec 2007
Finished
Dec 2007